Affiliation:
1. Associate Editor, The Senior Care Pharmacist
Abstract
The US Food and Drug Administration’s approval of anti-amyloid therapies for the treatment of Alzheimer’s dementia has resulted in a proliferation of publications reporting and conveying rapidly changing information. Unfortunately for the clinician, this information is surfacing
in a variety of places and formats without a unifying consensus or clear guidance.
Publisher
American Society of Consultant Pharmacists
Reference19 articles.
1. Aducanumab: appropriate use recommendations;J Prev Alzheimers Dis.,2021
2. A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer’s Disease (Clarity AD).;NIH Clinical
3. Prescribing Information.;LEQEMBI website.
4. Lecanemab: appropriate use recommendations.;J Prev Alzheimers Dis.,2023
5. Lecanemab, aducanumab, and gantenerumab-binding profiles to different forms of amyloid-beta might explain efficacy and side effects in clinical trials for Alzheimer’s disease.;Neurotherapeutics.,2023
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. It Takes a Village…;The Senior Care Pharmacist;2024-08-01